Compare Gilead Sciences, Inc. (GILD) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sirius XM Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Sirius XM Holdings Inc trades at $28.42 (market cap $9.70B). The key difference: Gilead Sciences, Inc. is far larger — about 17.4× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| GILD | SIRI | |
|---|---|---|
Market Cap | $168.35B | $9.70B |
Sector | Health | Media |
52-Week High | $155.80 | $32.59 |
52-Week Low | $110.56 | $19.92 |
Enterprise Value | $191.42B | $18.98B |
Dividend Yield | 2.42% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Sirius XM Holdings (SIRI) trades at $28.40, down 1.32% with bearish technical signals despite attractive valuation metrics including P/E of 11.56 and P/B of 0.81. The company reported mixed Q2 2026 results with a revenue beat but earnings miss, while maintaining stable cash flow and announcing a $0.27 dividend. Recent news highlights satellite communications growth potential and institutional positioning.
SIRI presents a value opportunity with strong cash generation and dividend yield, though near-term headwinds include subscriber challenges and debt levels. Analyst consensus remains bullish with $33.17 price target representing 17% upside, but investors should monitor execution on subscriber retention and competitive pressures in the evolving audio streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
